

CURRICULUM VITAE

Name: Yangmu Huang
Position Title: Deputy Director, Associate Researcher, and Doctoral Supervisor,
Department of Global Health, School of Public Health, Peking
University
Research field: Pharmaceutical R&D and global health, global health security,
nutrition and food safety, public health preparedness and response
Contact information: 15010376131
Email: ymhuang@bjmu.edu.cn
Photo:

Brief introduction

Dr. Yangmu Huang is the Deputy Director, Associate Researcher, and Doctoral Supervisor at the Department of Global Health, School of Public Health, Peking University. She earned her PhD in Nutrition and Food Safety from the School of Public Health and did two years' post-doctoral research in the School of Pharmaceutical Science at Peking University. With a multidisciplinary background, she mainly focuses on the cross-study of pharmaceutical R&D and global health, intending to improve the accessibility and availability of medical products to disadvantaged groups. She has hosted and participated in several international- and national-level research projects, such as the National Natural Science Foundation of China and the UK DFID Global Health Support Programme. She has published over 50 articles in peer-reviewed journals and taught multiple courses related to global health.

Dr. Huang currently serves as the deputy secretary-general of the Public Health and Preventive Medicine Branch of the China International Exchange and Promotive Association, the deputy secretary-general of the Beijing International Medical Exchange Association; the council member of the Public Health Branch of the Chinese Medical Rescue Association, the Public Health Emergency Work Committee of the Chinese Society of Emergency Management as well as the Chinese Research Hospital Association.

As the senior consultant of China's Delegation, she has been invited to attend the World Health Assembly and the Executive Board of the World Health Organization every year. She has also provided technical consultation to the National Health Commission, the World Health Organizations and other United Nations organizations. Due to her contribution and achievements, she was nominated by the Chinese Academy of Engineering and selected as the "Health Young Physician Leaders" in 2019 by the International Academy Partnership.

Detailed introduction

Research focus

Challenges and opportunities for China entering global research and development for emerging infectious diseases (EIDs): A case study of China's Ebola-related research and development

This study analyzed the R&D process of Ebola-related medical products in China and discussed the opportunities and challenges for China entering global research and development (R&D) for EIDs. It also explored effective incentive mechanisms for promoting pharmaceutical

R&D and provided policy recommendation to better respond to these opportunities and challenges. The study suggested that China had an advantageous organizational structure and R&D system to support the R&D of crisis-critical EID products that lack market incentives in the early stages, such as Ebola. However, it is necessary to strengthen the construction of early R&D technology platforms, and promote bilateral and multilateral international cooperation in Phase III clinical trials with innovative approaches to increase access to medicines.

Considering the significance of pharmaceutical innovation during public health emergencies, we proposed to establish innovative modes for improving R&D for EIDs in China based on crisis management and innovation-driven theories. It is necessary to identify the national R&D core product needs before disease outbreak and the optimal “push-pull” incentive and funding mechanisms suitable for China’s situation. The study will produce better-informed and sound R&D innovation modes for policymakers with both theoretical and empirical evidence. It will also provide strategic insights into China's better involvement in the prevention and control of emerging infectious diseases in the post-COVID-19 future.

Main publications

1. Chao Li, Jingyi Chen, **Yangmu Huang***. Challenges and opportunities for China entering global research and development for emerging infectious diseases: a case study of China’s Ebola related research and development. *Infectious Diseases of Poverty*, 2020,9(27).
2. Yuanjie Pang, Qi Wang, Min Lv*, Mengke Yu, Ming Lu, **Yangmu Huang***, Jiang Wu, Zheng Xie. Influenza vaccination and hospitalization outcomes among older patients with cardiovascular or respiratory diseases. *The Journal of Infectious Diseases*, 2020, 11:jjaa493.
3. Jingqi Song, Ji Zhang, Wafaie Fawzi, **Yangmu Huang***. Double burden of malnutrition among Chinese women of reproductive age and their social determinants. *Nutrients*, 2020, 12(10):3102.
4. Zihui Li, Xinyi Li*, Christopher R. Sudfeld, Yuning Liu, Kun Tang, **Yangmu Huang***, Wafaie Fawzi. The Effect of the Yingyangbao Complementary Food Supplement on the Nutritional Status of Infants and Children: A Systematic Review and Meta-Analysis. *Nutrients*, 2019,11,2404.
5. **Yangmu Huang***, Ke Pan, Danlu Peng, Andy Stergachis. A qualitative assessment of the challenges of WHO prequalification for anti-malarial drugs in China. *Malaria Journal*, 2018, 17(149):1~9.
6. Yan Guo*, **Yangmu Huang**. Realising equity in maternal health: China's successes and challenges. *Lancet*, 2018. DOI: 10.1016/S0140-6736(18)32464-4.
7. **Yangmu Huang**, Luwen Shi, Rui She, Jing Bai, Shiyong Jiao, Yan Guo*. Domestic trends in malaria research and development in China and its global influence. *Infectious Diseases of Poverty*, 2017, 6(4):1~9.
8. **Yangmu Huang**, Qipeng Zhao, Qiaomeng Ren, Danlu Peng, Yan Guo*. The production and sales of antituberculosis drugs in China. *Infectious Diseases of Poverty*, 2016, 5(88): 1~8.
9. **Yangmu Huang**, Hui Li, Danlu Peng, Yu Wang, Qiaomeng Ren, Yan Guo*. The production and exportation of artemisinin-derived drugs in China: current status and existing challenges. *Malaria Journal*, 2016, 15(356): 1~8.
10. Yan Guo*, **Yangmu Huang**. New challenges for tuberculosis control in China. *Lancet Global Health*, 2016, 4(7): e434~e435.